These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 35531791)

  • 1. Tyrosine kinase inhibitors and tumor lysis syndrome in hematologic malignancies: A systemic review.
    Salter B; Burns I; Fuller K; Eshaghpour A; Lionel AC; Crowther M
    Eur J Haematol; 2022 Aug; 109(2):166-181. PubMed ID: 35531791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor lysis syndrome in the era of novel and targeted agents in patients with hematologic malignancies: a systematic review.
    Howard SC; Trifilio S; Gregory TK; Baxter N; McBride A
    Ann Hematol; 2016 Mar; 95(4):563-73. PubMed ID: 26758269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
    Cheson BD; Heitner Enschede S; Cerri E; Desai M; Potluri J; Lamanna N; Tam C
    Oncologist; 2017 Nov; 22(11):1283-1291. PubMed ID: 28851760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies.
    McBride A; Westervelt P
    J Hematol Oncol; 2012 Dec; 5():75. PubMed ID: 23237230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of rasburicase over standard of care for the prevention and treatment of tumor lysis syndrome in children with hematologic malignancies in China.
    Hu S; Han Y; Zhang W; Zhang T; Yao X; Liu L
    J Med Econ; 2019 Aug; 22(8):742-750. PubMed ID: 30939962
    [No Abstract]   [Full Text] [Related]  

  • 6. Single-Dose Rasburicase Might Be Adequate To Overcome Tumor Lysis Syndrome In Hematological Malignancies.
    Yaman S; Başcı S; Turan G; Ulu BU; Yiğenoğlu TN; Dal MS; Kızıl Çakar M; Altuntaş F
    Clin Lymphoma Myeloma Leuk; 2022 Feb; 22(2):e71-e76. PubMed ID: 34565690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.
    Spina M; Nagy Z; Ribera JM; Federico M; Aurer I; Jordan K; Borsaru G; Pristupa AS; Bosi A; Grosicki S; Glushko NL; Ristic D; Jakucs J; Montesinos P; Mayer J; Rego EM; Baldini S; Scartoni S; Capriati A; Maggi CA; Simonelli C;
    Ann Oncol; 2015 Oct; 26(10):2155-61. PubMed ID: 26216382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies.
    Verma D; Kantarjian H; Strom SS; Rios MB; Jabbour E; Quintas-Cardama A; Verstovsek S; Ravandi F; O'Brien S; Cortes J
    Blood; 2011 Oct; 118(16):4353-8. PubMed ID: 21846902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rasburicase in tumor lysis syndrome of the adult: a systematic review and meta-analysis.
    Lopez-Olivo MA; Pratt G; Palla SL; Salahudeen A
    Am J Kidney Dis; 2013 Sep; 62(3):481-92. PubMed ID: 23684124
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.
    Cheuk DK; Chiang AK; Chan GC; Ha SY
    Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous tumor lysis syndrome in a patient with chronic myeloid leukemia treated successfully with allopurinol.
    Gartenberg A; Winkel M; Leonard N
    Am J Emerg Med; 2024 Apr; 78():242.e1-242.e3. PubMed ID: 38007380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Effect of the Administration Period of Rasburicase in Japanese Adult Hematological Malignancy Patients at High-Risk for Tumor Lysis Syndrome].
    Kobayashi S; Yasu T; Sato K; Ohno N; Kuroda S
    Gan To Kagaku Ryoho; 2018 May; 45(5):879-881. PubMed ID: 30026457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review of tumour lysis syndrome with targeted therapies and the role of rasburicase.
    Bose P; Qubaiah O
    J Clin Pharm Ther; 2011 Jun; 36(3):299-326. PubMed ID: 21501203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour lysis syndrome and acute kidney injury in high-risk haematology patients in the rasburicase era. A prospective multicentre study from the Groupe de Recherche en Réanimation Respiratoire et Onco-Hématologique.
    Darmon M; Vincent F; Camous L; Canet E; Bonmati C; Braun T; Caillot D; Cornillon J; Dimicoli S; Etienne A; Galicier L; Garnier A; Girault S; Hunault-Berger M; Marolleau JP; Moreau P; Raffoux E; Recher C; Thiebaud A; Thieblemont C; Azoulay E;
    Br J Haematol; 2013 Aug; 162(4):489-97. PubMed ID: 23772757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor lysis syndrome.
    Jeha S
    Semin Hematol; 2001 Oct; 38(4 Suppl 10):4-8. PubMed ID: 11694945
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rasburicase for the prevention and treatment of hyperuricemia in tumor lysis syndrome.
    Kennedy LD; Ajiboye VO
    J Oncol Pharm Pract; 2010 Sep; 16(3):205-13. PubMed ID: 19923162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rasburicase for the treatment of tumor lysis in hematological malignancies.
    Malaguarnera G; Giordano M; Malaguarnera M
    Expert Rev Hematol; 2012 Feb; 5(1):27-38. PubMed ID: 22272702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose rasburicase in hematologic malignancies.
    Jayabose S; Kumar V; Dhanabalan R; Rajan P; Rathnam K; Viswanathan TK
    Indian J Pediatr; 2015 May; 82(5):458-61. PubMed ID: 25338496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carfilzomib-associated tumor lysis syndrome.
    Shely RN; Ratliff PD
    Pharmacotherapy; 2014 May; 34(5):e34-7. PubMed ID: 24390940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How we treat tumor lysis syndrome.
    Muslimani A; Chisti MM; Wills S; Nadeau L; Zakalik D; Daw H; Huang J; Jaiyesimi I
    Oncology (Williston Park); 2011 Apr; 25(4):369-75. PubMed ID: 21618960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.